Company Overview and News
Share prices on Bursa Malaysia continued lower at mid-morning. — Bernama picKUALA LUMPUR, Sept 18 — Share prices on Bursa Malaysia continued lower at mid-morning as traders remained on the sidelines, looking for clues as to market direction, dealers said.
KUALA LUMPUR, Aug 2 — Gains in heavyweights lifted the benchmark FTSE Bursa Malaysia KLCI (FBM KLCI) to close higher for the second consecutive day today, amid weak sentiment in the broader market.
KUALA LUMPUR, July 31 — Bursa Malaysia ended lower today, weighed down by losses in the finance stocks as well as profit-taking in the broader market after recent gains, said dealers.
KUALA LUMPUR, July 31 — Bursa Malaysia remained in negative territory at mid-afternoon, on a lack of catalysts.
KUALA LUMPUR, July 31 — Bursa Malaysia was in negative territory at mid-morning in line with its easier regional peers, with selected heavyweights, including Petronas Gas and CIMB showing subdued trading.
Bursa Malaysia resumed afternoon session on a easier note, reversing its earlier gains on the back of weak buying momentum especially for bluechips in Kuala Lumpur June 29, 2017. — Bernama picKUALA LUMPUR, July 28 — Bursa Malaysia stayed in negative territory at mid-afternoon, as losses in key heavyweights continued to weigh on the local market.
KUALA LUMPUR, July 13 — Bursa Malaysia opened higher this morning, prompted by the rise in US equity and Treasury yields, after remarks by Federal Reserve Chair Janet Yellen that US policymakers were watching inflation very closely given its failure to improve as targeted by the central bank.
KUALA LUMPUR, June 13 — Bursa Malaysia opened lower this morning in line with the weaker performance on Wall Street yesterday but recovered thereafter, said a dealer.
KUALA LUMPUR, June 8 ― Share prices on Bursa Malaysia closed lower today on extended consolidation amid mild profit-taking and lack of participation from regular institutional and retail investors, dealers said.
KUALA LUMPUR, June 8 — Bursa Malaysia finished the morning session marginally higher spurred by light buying in small-capitalised stocks and selected blue chips.
KUALA LUMPUR, June 8 — Share prices on Bursa Malaysia were mixed at mid-morning although the key index recovered from earlier losses to cross into the positive territory.
KUALA LUMPUR, June 8 — Share prices on Bursa Malaysia edged lower this morning on selective trading as traders remained on the sidelines, awaiting fresh leads, dealers said.
An investor monitors share market prices at a brokerage firm in Kuala Lumpur, Malaysia, August 24, 2015. — Reuters picKUALA LUMPUR, April 12 — Bursa Malaysia continued to trade higher at mid-day today as the market rebounded from recent oversold trading.
An investor monitors share market prices at a brokerage firm in Kuala Lumpur, Malaysia, August 24, 2015. — Reuters picKUALA LUMPUR, April 12 — Overbought correction prompted Bursa Malaysia to turn higher at mid-morning, dealers said.
KUALA LUMPUR (April 12): The FBM KLCI eked out marginal gains at the midday break today as sellers led buyers at the local market.
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
2018-05-17 - Asif
Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...